Among patients with type 2 diabetes mellitus who do not achieve optimal glycemic control with insulin monotherapy, is the addition of oral hypoglycemic agents associated with benefits (measured by lowering of hemoglobin A1c) or adverse effects?
Adding a sulfonylurea to insulin was associated with more hypoglycemic events compared with insulin alone, but this association was not observed for metformin. Adding a sulfonylurea or metformin to insulin was associated with a decrease in hemoglobin A1c of approximately 1.0%.
Vos RC, Rutten GEHM. Oral Hypoglycemic Agents Added to Insulin Monotherapy for Type 2 Diabetes. JAMA. 2017;318(15):1489–1490. doi:10.1001/jama.2017.13463
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: